User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.

Primary tabs

download
  • Open access
  • PDF
  • 2.38 M
van der Ploeg, Ans T Kruijshaar, Michelle E Toscano, Antonio Laforêt, Pascal Angelini, Corrado Van den Bergh, Peter [UCL] European Pompe Consortium

(eng) BACKGROUND AND PURPOSE: Pompe disease is a rare inheritable muscle disorder for which enzyme replacement therapy (ERT) has been available since 2006. Uniform criteria for starting and stopping ERT in adult patients were developed and reported here. METHODS: Three consensus meetings were organized through the European Pompe Consortium, a network of experts from 11 European countries in the field of Pompe disease. A systematic review of the literature was undertaken to determine the effectiveness of ERT in adult patients on a range of clinical outcome measures and quality of life. A narrative synthesis is presented. RESULTS: Consensus was reached on how the diagnosis of Pompe disease should be confirmed, when treatment should be started, reasons for stopping treatment and the use of ERT during pregnancy. This was based on expert opinion and supported by the literature. One clinical trial and 43 observational studies, covering a total of 586 individual adult patients, provided evidence of a beneficial effect of ERT at group level. At individual patient level, the response to treatment varied, but factors associated with a patient's response to ERT were not described in many studies. Eleven observational studies focused on more severely affected patients, suggesting that ERT can also be beneficial in these patients. There are no studies on the effects of ERT in pre-symptomatic patients. CONCLUSIONS: This is the first European consensus recommendation for starting and stopping ERT in adult patients with Pompe disease, based on the extensive experience of experts from different countries.

Document type Article de périodique (Journal article) – Synthèse de littérature
Access type Accès libre
Publication date 2017
Language Anglais
Journal information "European Journal of Neurology" - Vol. 24, no. 6, p. 768-779; e29-e31 (2017)
Peer reviewed yes
Publisher Wiley-Blackwell Publishing Ltd. ((United Kingdom) Oxford)
issn 1351-5101
e-issn 1468-1331
Publication status Publié
Affiliations UCL - SSS/IONS/NEUR - Clinical Neuroscience
UCL - (SLuc) Service de neurologie
Keywords Pompe disease ; adult patients ; alglucosidase alfa ; enzyme replacement therapy ; guidelines ; treatment recommendations
Links
  1. Hagemans M. L. C., Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients, 10.1093/brain/awh384
  2. van der Beek Nadine AME, de Vries Juna M, Hagemans Marloes LC, Hop Wim CJ, Kroos Marian A, Wokke John HJ, de Visser Marianne, van Engelen Baziel GM, Kuks Jan BM, van der Kooi Anneke J, Notermans Nicolette C, Faber Karin G, Verschuuren Jan JGM, Reuser Arnold JJ, van der Ploeg Ans T, van Doorn Pieter A, Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study, 10.1186/1750-1172-7-88
  3. Amalfitano, Genet Med, 3, 132 (2001)
  4. Kishnani P. S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W. L., Leslie N., Levine J., Spencer C., McDonald M., Li J., Dumontier J., Halberthal M., Chien Y. H., Hopkin R., Vijayaraghavan S., Gruskin D., Bartholomew D., van der Ploeg A., Clancy J. P., Parini R., Morin G., Beck M., De la Gastine G. S., Jokic M., Thurberg B., Richards S., Bali D., Davison M., Worden M. A., Chen Y. T., Wraith J. E., Recombinant human acid  -glucosidase: Major clinical benefits in infantile-onset Pompe disease, 10.1212/01.wnl.0000251268.41188.04
  5. Kishnani Priya Sunil, Nicolino Marc, Voit Thomas, Rogers R. Curtis, Tsai Anne Chun-Hui, Waterson John, Herman Gail E., Amalfitano Andreas, Thurberg Beth L., Richards Susan, Davison Mark, Corzo Deyanira, Chen Y.T., Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe disease, 10.1016/j.jpeds.2006.02.035
  6. Van den Hout Hannerieke, Reuser Arnold JJ, Vulto Arnold G, Christa B Loonen M, Cromme-Dijkhuis Adri, Van der Ploeg Ans T, Recombinant human α-glucosidase from rabbit milk in Pompe patients, 10.1016/s0140-6736(00)02533-2
  7. Anderson L. J., Henley W., Wyatt K. M., Nikolaou V., Waldek S., Hughes D. A., Lachmann R. H., Logan S., Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study, 10.1007/s10545-014-9728-1
  8. Angelini C., , Semplicini C., Ravaglia S., Bembi B., Servidei S., Pegoraro E., Moggio M., Filosto M., Sette E., Crescimanno G., Tonin P., Parini R., Morandi L., Marrosu G., Greco G., Musumeci O., Di Iorio G., Siciliano G., Donati M. A., Carubbi F., Ermani M., Mongini T., Toscano A., Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years, 10.1007/s00415-011-6293-5
  9. Bembi Bruno, Pisa Federica Edith, Confalonieri Marco, Ciana Giovanni, Fiumara Agata, Parini Rossella, Rigoldi Miriam, Moglia Arrigo, Costa Alfredo, Carlucci Annalisa, Danesino Cesare, Pittis Maria Gabriela, Dardis Andrea, Ravaglia Sabrina, Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II, 10.1007/s10545-010-9201-8
  10. de Vries Juna M, van der Beek Nadine AME, Hop Wim CJ, Karstens Francois PJ, Wokke John H, de Visser Marianne, van Engelen Baziel GM, Kuks Jan BM, van der Kooi Anneke J, Notermans Nicolette C, Faber Catharina G, Verschuuren Jan JGM, Kruijshaar Michelle E, Reuser Arnold JJ, van Doorn Pieter A, van der Ploeg Ans T, Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study, 10.1186/1750-1172-7-73
  11. Güngör Deniz, Kruijshaar Michelle E, Plug Iris, D’Agostino Ralph B, Hagemans Marloes LC, van Doorn Pieter A, Reuser Arnold JJ, van der Ploeg Ans T, Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study, 10.1186/1750-1172-8-49
  12. Regnery Caroline, Kornblum Cornelia, Hanisch Frank, Vielhaber Stefan, Strigl-Pill Nicola, Grunert Birgit, Müller-Felber Wolfgang, Glocker Franz Xaver, Spranger Matthias, Deschauer Marcus, Mengel Eugen, Schoser Benedikt, 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy, 10.1007/s10545-012-9451-8
  13. Strothotte S., Strigl-Pill N., Grunert B., Kornblum C., Eger K., Wessig C., Deschauer M., Breunig F., Glocker F. X., Vielhaber S., Brejova A., Hilz M., Reiners K., Müller-Felber W., Mengel E., Spranger M., Schoser Benedikt, Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial, 10.1007/s00415-009-5275-3
  14. van der Ploeg Ans T., Barohn Richard, Carlson Lisa, Charrow Joel, Clemens Paula R., Hopkin Robert J., Kishnani Priya S., Laforêt Pascal, Morgan Claire, Nations Sharon, Pestronk Alan, Plotkin Horacio, Rosenbloom Barry E., Sims Katherine B., Tsao Elisa, Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa, 10.1016/j.ymgme.2012.09.015
  15. van der Ploeg Ans T., Clemens Paula R., Corzo Deyanira, Escolar Diana M., Florence Julaine, Groeneveld Geert Jan, Herson Serge, Kishnani Priya S., Laforet Pascal, Lake Stephen L., Lange Dale J., Leshner Robert T., Mayhew Jill E., Morgan Claire, Nozaki Kenkichi, Park Dorothy J., Pestronk Alan, Rosenbloom Barry, Skrinar Alison, van Capelle Carine I., van der Beek Nadine A., Wasserstein Melissa, Zivkovic Sasa A., A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease, 10.1056/nejmoa0909859
  16. Schoser, J Neurol (2016)
  17. Toscano Antonio, Schoser Benedikt, Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review, 10.1007/s00415-012-6636-x
  18. Barba-Romero, Rev Neurol, 54, 497 (2012)
  19. Cupler Edward J., Berger Kenneth I., Leshner Robert T., Wolfe Gil I., Han Jay J., Barohn Richard J., Kissel John T., , Consensus treatment recommendations for late-onset Pompe disease, 10.1002/mus.22329
  20. Al Jasmi Fatma, , Al Jumah Mohammed, Alqarni Fatimah, Al-Sanna’a Nouriya, Al-Sharif Fawziah, Bohlega Saeed, Cupler Edward J., Fathalla Waseem, Hamdan Mohamed A., Makhseed Nawal, Nafissi Shahriar, Nilipour Yalda, Selim Laila, Shembesh Nuri, Sunbul Rawda, Tonekaboni Seyed Hassan, Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group, 10.1186/s12883-015-0412-3
  21. Hundsberger Thomas, Rohrbach Marianne, Kern Lukas, Rösler Kai M., Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease, 10.1007/s00415-013-6980-5
  22. Llerena Junior, Arq Neuropsiquiatr, 1 (2015)
  23. Tarnopolsky, Can J Neurol Sci, 1 (2016)
  24. Schüller A., Kornblum C., Deschauer M., Vorgerd M., Schrank B., Mengel E., Lukacs Z., Gläser D., Young P., Plöckinger U., Schoser B., Diagnose und Therapie des Late-onset-Morbus-Pompe, 10.1007/s00115-013-3947-9
  25. Schoser Benedikt, Laforêt Pascal, Kruijshaar Michelle E., Toscano Antonio, van Doorn Pieter A., van der Ploeg Ans T., 208th ENMC International Workshop: Formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26–28 September 2014, 10.1016/j.nmd.2015.04.006
  26. Güngör Deniz, de Vries Juna M., Brusse Esther, Kruijshaar Michelle E., Hop Wim C.J., Murawska Magda, van den Berg Linda E.M., Reuser Arnold J.J., van Doorn Pieter A., Hagemans Marloes L.C., Plug Iris, van der Ploeg Ans T., Enzyme replacement therapy and fatigue in adults with Pompe disease, 10.1016/j.ymgme.2013.03.016
  27. Güngör Deniz, Kruijshaar Michelle E., Plug Iris, Rizopoulos Dimitris, Kanters Tim A., Wens Stephan C. A., Reuser Arnold J. J., van Doorn Pieter A., van der Ploeg Ans T., Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up, 10.1007/s10545-015-9889-6
  28. Vianello Andrea, Semplicini Claudio, Paladini Luciana, Concas Alessandra, Ravaglia Sabrina, Servidei Serenella, Toscano Antonio, Mongini Tiziana, Angelini Corrado, Pegoraro Elena, Enzyme Replacement Therapy Improves Respiratory Outcomes in Patients with Late-Onset Type II Glycogenosis and High Ventilator Dependency, 10.1007/s00408-013-9489-x
  29. van der Meijden J. C., Güngör D., Kruijshaar M. E., Muir A. D. J., Broekgaarden H. A., van der Ploeg A. T., Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease, 10.1007/s10545-014-9751-2
  30. Orlikowski David, Pellegrini Nadine, Prigent Hélène, Laforêt Pascal, Carlier Robert, Carlier Pierre, Eymard Bruno, Lofaso Frédéric, Annane Djillali, Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease, 10.1016/j.nmd.2011.04.001
  31. Papadimas G.K., Spengos K., Konstantinopoulou A., Vassilopoulou S., Vontzalidis A., Papadopoulos C., Michelakakis H., Manta P., Adult Pompe disease: Clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy, 10.1016/j.clineuro.2010.12.005
  32. Stepien Karolina M., Hendriksz Christian J., Roberts Mark, Sharma Reena, Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years, 10.1016/j.ymgme.2016.01.013
  33. Lukacs Zoltan, Nieves Cobos Paulina, Wenninger Stephan, Willis Tracey A., Guglieri Michela, Roberts Marc, Quinlivan Rosaline, Hilton-Jones David, Evangelista Teresinha, Zierz Stephan, Schlotter-Weigel Beate, Walter Maggie C., Reilich Peter, Klopstock Thomas, Deschauer Marcus, Straub Volker, Müller-Felber Wolfgang, Schoser Benedikt, Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness, 10.1212/wnl.0000000000002758
  34. Bergsma Atze J, in ‘t Groen Stijn LM, Verheijen Frans W, van der Ploeg Ans T, Pijnappel WWM Pim, From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides, 10.1038/mtna.2016.75
  35. Angelini Corrado, Semplicini Claudio, Tonin Paola, Filosto Massimiliano, Pegoraro Elena, Sorarù Gianni, Fanin Marina, Progress in enzyme replacement therapy in glycogen storage disease type II, 10.1177/1756285609103324
  36. Echaniz-Laguna Andoni, Carlier Robert-Yves, Laloui Kenza, Carlier Pierre, Salort-Campana Emmanuelle, Pouget Jean, Laforet Pascal, SHOULD patients with asymptomatic pompe disease be treated? A nationwide study in france : Asymptomatic Pompe Disease, 10.1002/mus.24653
  37. Laloui K., Wary C., Carlier R.- Y., Hogrel J.- Y., Caillaud C., Laforet P., Making diagnosis of Pompe disease at a presymptomatic stage: To treat or not to treat?, 10.1212/wnl.0b013e318228c0ea
  38. Case Laura E., Koeberl Dwight D., Young Sarah P., Bali Deeksha, DeArmey Stephanie M., Mackey Joanne, Kishnani Priya S., Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: A case study, 10.1016/j.ymgme.2008.09.001
  39. Furusawa Yoshihiko, Mori-Yoshimura Madoka, Yamamoto Toshiyuki, Sakamoto Chikako, Wakita Mizuki, Kobayashi Yoko, Fukumoto Yutaka, Oya Yasushi, Fukuda Tokiko, Sugie Hideo, Hayashi Yukiko K., Nishino Ichizo, Nonaka Ikuya, Murata Miho, Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study, 10.1007/s10545-011-9393-6
  40. Kobayashi Hiroshi, Shimada Yohta, Ikegami Masahiro, Kawai Toshinao, Sakurai Ken, Urashima Takashi, Ijima Masatoshi, Fujiwara Masako, Kaneshiro Eiko, Ohashi Toya, Eto Yoshikatsu, Ishigaki Keiko, Osawa Makiko, Kyosen Sandra Obikawa, Ida Hiroyuki, Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: From our experience of 4 cases including an autopsy case, 10.1016/j.ymgme.2010.01.015
  41. Korpela Mari P., Paetau Anders, Löfberg Mervi I., Timonen Marjut H., Lamminen Antti E., Kiuru-Enari Sari M.K., A novel mutation of the GAA gene in a Finnish late-onset pompe disease patient: Clinical phenotype and follow-up with enzyme replacement therapy, 10.1002/mus.21291
  42. Ravaglia Sabrina, Danesino Cesare, Pichiecchio Anna, Repetto Alessandra, Poloni Guy Umberto, Rossi Miriam, Fratino Pietro, Moglia Arrigo, Costa Alfredo, Enzyme replacement therapy in severe adult-onset glycogen storage disease type II, 10.1007/s12325-008-0086-y
  43. Rossi Massimiliano, Parenti Giancarlo, Della Casa Roberto, Romano Alfonso, Mansi Giuseppina, Agovino Teresa, Rosapepe Felice, Vosa Carlo, Del Giudice Ennio, Andria Generoso, Long-Term Enzyme Replacement Therapy for Pompe Disease With Recombinant Human Alpha-glucosidase Derived From Chinese Hamster Ovary Cells, 10.1177/0883073807302598
  44. Sayeed, Respirol Case Rep, 3, 159 (2015)
  45. Sugai Fuminobu, Kokunai Yosuke, Yamamoto Yoichi, Hashida Goichi, Shimazu Kengo, Mihara Masahito, Inoue Satoru, Sakoda Saburo, Use of the muscle volume analyzer to evaluate enzyme replacement therapy in late-onset Pompe disease, 10.1007/s00415-009-5367-0
  46. van Capelle C.I., Winkel L.P.F., Hagemans M.L.C., Shapira S.K., Arts W.F.M., van Doorn P.A., Hop W.C.J., Reuser A.J.J., van der Ploeg A.T., Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease, 10.1016/j.nmd.2008.04.009
  47. Kishnani Priya S., Goldenberg Paula C., DeArmey Stephanie L., Heller James, Benjamin Danny, Young Sarah, Bali Deeksha, Smith Sue Ann, Li Jennifer S., Mandel Hanna, Koeberl Dwight, Rosenberg Amy, Chen Y-T, Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants, 10.1016/j.ymgme.2009.08.003
  48. van Gelder Carin M., Hoogeveen-Westerveld Marianne, Kroos Marian A., Plug Iris, van der Ploeg Ans T., Reuser Arnold J. J., Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease, 10.1007/s10545-014-9707-6
  49. de Vries Juna M., Kuperus Esther, Hoogeveen-Westerveld Marianne, Kroos Marian A., Wens Stephan C.A., Stok Merel, van der Beek Nadine A.M.E., Kruijshaar Michelle E., Rizopoulos Dimitris, van Doorn Pieter A., van der Ploeg Ans T., Pijnappel W.W.M. Pim, Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy, 10.1038/gim.2016.70
  50. Patel Trusha T., Banugaria Suhrad G., Case Laura E., Wenninger Stephan, Schoser Benedikt, Kishnani Priya S., The impact of antibodies in late-onset Pompe disease: A case series and literature review, 10.1016/j.ymgme.2012.04.027
  51. Dasouki Majed, Jawdat Omar, Almadhoun Osama, Pasnoor Mamatha, McVey April L., Abuzinadah Ahmad, Herbelin Laura, Barohn Richard J., Dimachkie Mazen M., Pompe Disease, 10.1016/j.ncl.2014.04.010
  52. de Vries Juna M., Brugma Jan-Dietert C., Özkan Lale, Steegers Eric A.P., Reuser Arnold J.J., van Doorn Pieter A., van der Ploeg Ans T., First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease, 10.1016/j.ymgme.2011.09.012
  53. Dons-Sinke, Case Rep Anesthesiol, 2014, 650310 (2014)
  54. Zagnoli Fabien, Leblanc Amelie, Blanchard Christian, Pregnancy during enzyme replacement therapy for late-onset acid maltase deficiency, 10.1016/j.nmd.2012.11.006
  55. Van den Hout J. M. P., Kamphoven J. H. J., Winkel L. P. F., Arts W. F. M., Klerk J. B. C. D., Loonen M. C. B., Vulto A. G., Cromme-Dijkhuis A., Weisglas-Kuperus N., Hop W., Hirtum H. V., Diggelen O. P. V., Boer M., Kroos M. A., Doorn P. A. V., Voort E. V. d., Sibbles B., Corven E. J. J. M. V., Brakenhoff J. P. J., Hove J. V., Smeitink J. A. M., Jong G. d., Reuser A. J. J., Ploeg A. T. V. d., Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human  -Glucosidase From Milk, 10.1542/peds.113.5.e448
  56. 4180000, in Moniteur Belge/Belgisch staatsblad 2011 47840 47846
  57. Vielhaber Stefan, Brejova Andrea, Debska-Vielhaber Grazyna, Kaufmann Joern, Feistner Helmut, Schoenfeld Mircea A., Awiszus Friedemann, 24-Months results in two adults with Pompe disease on enzyme replacement therapy, 10.1016/j.clineuro.2010.09.016
  58. Merk T., Wibmer T., Schumann C., Krüger S., Glycogen storage disease type II (Pompe disease) - influence of enzyme replacement therapy in adults, 10.1111/j.1468-1331.2008.02377.x
  59. Andreassen Christer Swan, Schlütter Jacob Mørup, Vissing John, Andersen Henning, Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease—a long-term follow-up, 10.1016/j.ymgme.2014.02.015
  60. Gesquière-Dando Aude, Attarian Shahram, Maues De Paula André, Pouget Jean, Salort-Campana Emmanuelle, Fibromyalgia-like symptoms associated with irritable bowel syndrome: A challenging diagnosis of late-onset Pompe disease : Fibromyalgia-Like Symptoms and Late-Onset Pompe Disease, 10.1002/mus.24618
  61. Angelini Corrado, Semplicini Claudio, Ravaglia Sabrina, Moggio Maurizio, Comi Giacomo P., Musumeci Olimpia, Pegoraro Elena, Tonin Paola, Filosto Massimiliano, Servidei Serenella, Morandi Lucia, Crescimanno Grazia, Marrosu Giovanni, Siciliano Gabriele, Mongini Tiziana, Toscano ANTONIO, , New motor outcome function measures in evaluation of Late-Onset Pompe disease before and after enzyme replacement therapy, 10.1002/mus.23340
  62. Ravaglia S., Moglia A., Costa A., Repetto A., Danesino C., Enzyme replacement therapy in late-onset type II glycogenosis, 10.1111/j.1468-1331.2009.02667.x
  63. Ravaglia Sabrina, Pichiecchio Anna, Ponzio Michela, Danesino Cesare, Saeidi Garaghani Kolsoum, Poloni Guy Umberto, Toscano Antonio, Moglia Arrigo, Carlucci Annalisa, Bini Paola, Ceroni Mauro, Bastianello Stefano, Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response, 10.1007/s10545-010-9204-5
  64. Ravaglia Sabrina, De Filippi Paola, Pichiecchio Anna, Ponzio Michela, Saeidi Garaghani Kolsoum, Poloni Guy Umberto, Bini Paola, Danesino Cesare, Can genes influencing muscle function affect the therapeutic response to enzyme replacement therapy (ERT) in late-onset Type II Glycogenosis?, 10.1016/j.ymgme.2012.05.016
  65. Marzorati Mauro, Porcelli Simone, Bellistri Giuseppe, Morandi Lucia, Grassi Bruno, Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy, 10.1016/j.nmd.2012.10.017
  66. MARZORATI MAURO, PORCELLI SIMONE, REGGIORI BARBARA, MORANDI LUCIA, GRASSI BRUNO, Improved Exercise Tolerance after Enzyme Replacement Therapy in Pompe Disease : , 10.1249/mss.0b013e31823e6579
  67. Montagnese Federica, Barca E., Musumeci O., Mondello S., Migliorato A., Ciranni A., Rodolico C., De Filippi P., Danesino C., Toscano A., Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment, 10.1007/s00415-015-7664-0
  68. Crescimanno G., Modica R., Lo Mauro R., Musumeci O., Toscano A., Marrone O., Role of the cardio-pulmonary exercise test and six-minute walking test in the evaluation of exercise performance in patients with late-onset Pompe disease, 10.1016/j.nmd.2015.03.010
  69. Furusawa Yoshihiko, Mitsuhashi Satomi, Mori-Yoshimura Madoka, Shimada Yohta, Yamamoto Toshiyuki, Shibuya Makoto, Shimizu Jun, Ohashi Toya, Saito Yuko, Nishino Ichizo, Oya Yasushi, Murata Miho, Late-onset Pompe disease after 4 years of enzyme replacement therapy: An autopsy case, 10.1111/ncn3.66
  70. Isayama Reina, Shiga Kensuke, Seo Kazuya, Azuma Yumiko, Araki Yasukiyo, Hamano Ai, Takezawa Hedesato, Kuriyama Nagato, Takezawa Nobuo, Mizuno Toshiki, Nakagawa Masanori, Sixty Six–Month Follow-up of Muscle Power and Respiratory Function in a Case With Adult-Type Pompe Disease Treated With Enzyme Replacement Therapy : , 10.1097/cnd.0000000000000029
  71. Park Jin-Sung, Kim Hye-Gyung, Shin Jin-Hong, Choi Young-Chul, Kim Dae-Seong, Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up, 10.1007/s10072-014-2000-5
  72. de Vries Juna M., van der Beek Nadine A.M.E., Kroos Marian A., Özkan Lale, van Doorn Pieter A., Richards Susan M., Sung Crystal C.C., Brugma Jan-Dietert C., Zandbergen Adrienne A.M., van der Ploeg Ans T., Reuser Arnold J.J., High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa, 10.1016/j.ymgme.2010.08.009
  73. Winkel L�on P. F., Van den Hout Johanna M. P., Kamphoven Joep H. J., Disseldorp Janus A. M., Remmerswaal Maaike, Arts Willem F. M., Loonen M. Christa B., Vulto Arnold G., Van Doorn Pieter A., De Jong Gerard, Hop Wim, Smit G. Peter A., Shapira Stuart K., Boer Marijke A., Reuser Arnold J. J., Van der Ploeg Ans T., van Diggelen Otto P., Enzyme replacement therapy in late-onset Pompe's disease: A three-year follow-up, 10.1002/ana.20019
  74. Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, Klinger L, Hughes D, Waldek S, Lachmann R, Mehta A, Vellodi A, Logan S, The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders., 10.3310/hta16390
  75. Deegan PB Cox TM Waldek S Lachmann R Ramaswami U Jessop E Guidelines for the investigation and management of late onset acid maltase deficiency (Type II Glycogen Storage Disease/Pompe Disease) http://www.specialisedservices.nhs.uk/library/23/Guidelines_for_Late_Onset_Pompe_Disease.pdf
Bibliographic reference van der Ploeg, Ans T ; Kruijshaar, Michelle E ; Toscano, Antonio ; Laforêt, Pascal ; Angelini, Corrado ; et. al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.. In: European Journal of Neurology, Vol. 24, no. 6, p. 768-779; e29-e31 (2017)
Permanent URL http://hdl.handle.net/2078.1/199104